MartinBHyzinskiMD

Oncology • Scranton, PA

Physician

Join to view full profile

Are you Dr. Hyzinski?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 96 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
743 Jefferson Ave
Ste 205
Scranton, PA 18510
Phone+1 570-558-3020

Fax+1 570-558-3385

Summary

Dr. Martin Hyzinski, MD is an oncologist in Scranton, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with Regional Hospital of Scranton, Moses Taylor Hospital, and Geisinger Community Medical Center.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1984 - 1985
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1982 - 1984
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1979 - 1982
Perelman School of Medicine at the University of PennsylvaniaClass of 1979

Certifications & Licensure

PA State Medical License 1981 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Start of enrollment: 2007 Feb 28
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

32 citations
Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: inhibition of gr...
Janet L. Abrahm, Emmanuel C. Besa, M Hyzinski, Peter C. Nowell
Blood. 1986-05-01
59 citations
Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol.
Emmanuel C. Besa, Janet L. Abrahm, Mary Bartholomew, Martin Hyzinski, Peter C. Nowell
The American Journal of Medicine. 1990-12-01